DUNFERMLINE, Scozia–(BUSINESS WIRE)–Optos Plc, una controllata di Nikon Corporation, Japan e unica azienda di imaging retinico ultra-widefield per le cure oculistiche, è lieta di annunciare un accordo esclusivo di distribuzione per l’Europa e l’Austr…
Author: Business Wire
Samenvatting: Optos kondigt samenwerking aan voor het monitoren en behandelen van droge leeftijdsgerelateerde maculaire degeneratie in Europa
DUNFERMLINE, Schotland–(BUSINESS WIRE)–Optos Plc, een dochteronderneming van Nikon Corporation, Japan en het enige ultra-widefield retinale beeldvormingsbedrijf voor oogzorg is blij om een exclusieve distributie-overeenkomst in Europa en Australië aa…
Resumen: Optos anuncia colaboración para control y tratamiento de la degeneración macular seca asociada a la edad
DUNFERMLINE, Escocia–(BUSINESS WIRE)–Optos Plc, filial de Nikon Corporation (Japón) y la única empresa de imagen retiniana de campo de visión ultra-ancho para el tratamiento ocular ha anunciado un acuerdo de distribución exclusivo en Europa y Austral…
Oyster Point Announces Positive Results From Two Separate Phase 2b Clinical Trials of the Company’s Investigational Treatments for Dry Eye Disease
PRINCETON, N.J.–(BUSINESS WIRE)–Oyster Point Pharma, Inc., today announced results from the ONSET and RAINIER studies, two separate Phase 2b clinical trials evaluating the company’s novel therapies for the treatment of Dry Eye Disease (DED). Both stu…
MC2 Therapeutics anuncia resultados de primera línea que muestran perfil de seguridad favorable y reducción de la tinción corneal para el MC2-03 en pacientes de ojo seco con queratitis moderada a severa
COPENHAGE, Dinamarca–(BUSINESS WIRE)–Regulatory News : MC2 Therapeutics A/S, una compañía dermatológica y oftalmológica de estadio clínico, ha anunciado resultados de primera línea para el estudio de fase 2 MC2-03-C1 Northern Lights que valora la seg…
Optos Announces Collaboration for Monitoring and Treating Dry Age-Related Macular Degeneration in Europe
DUNFERMLINE, Scotland–(BUSINESS WIRE)–Optos Announces Collaboration for Monitoring and Treating Dry Age-Related Macular Degeneration in Europe
CVP Partners with Two Practices in Dayton, Ohio
DENVER–(BUSINESS WIRE)–#Denver–Revelstoke Capital, a Denver-based private equity firm announces their portfolio company CEI Visions has completed two more partnerships.
Novaliq Announces Positive Topline Results for Its SEECASE Phase 2 Trial of NOV03 for the Treatment of Patients with Dry Eye Disease
HEIDELBERG, Germany–(BUSINESS WIRE)–#CyclASol–Novaliq, a specialty pharmaceutical company for the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first water-free technology for ophth…
Novaliq Announces Positive Topline Results for Its SEECASE Phase 2 Trial of NOV03 for the Treatment of Patients with Dry Eye Disease
HEIDELBERG, Germany–(BUSINESS WIRE)–#CyclASol–Novaliq, a specialty pharmaceutical company for the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first water-free technology for ophth…
Mati Therapeutics Expands Intellectual Property Portfolio with 114 Patents Issued
AUSTIN, Texas–(BUSINESS WIRE)–Mati Therapeutics Inc. (“Mati”) announced that its international patent portfolio has grown to 114 issued patents, including recently granted U.S. Patent No. 9,849,082, titled “Nasolacrimal Drainage System Implants for D…
Ryan Murphy and David Miller Donate $10 Million to Children’s Hospital Los Angeles
LOS ANGELES–(BUSINESS WIRE)–On behalf of the Ford Theodore Miller Murphy Family, Emmy-Award winning writer, producer and director Ryan Murphy and his husband, photographer David Miller, have made a landmark $10 million gift to Children’s Hospital Los…
MC2 Therapeutics meldet Topline-Ergebnisse mit positivem Sicherheitsprofil und Reduzierung der kornealen Anfärbungen durch MC2-03 bei Patienten mit Trockenem Auge und mittlerer bis schwerer Keratitis
KOPENHAGEN, Dänemark–(BUSINESS WIRE)–MC2 Therapeutics A/S, ein Hersteller von Medikamenten für Haut- und Augenkrankheiten, gab heute Topline-Ergebnisse der Phase-2-Studie „MC2-03-C1 Northern Lights“ zur Sicherheit und Wirksamkeit von MC2-03 (PADciclo…
MC2 Therapeutics maakt toplijnresultaten bekend waaruit een gunstig veiligheidsprofiel en vermindering van corneale kleuring blijkt voor MC2-03 bij droge ogenpatiënten met matige tot ernstige keratitis
KOPENHAGEN, Denemarken–(BUSINESS WIRE)–MC2 Therapeutics A/S, een dermatologie- en oogzorgbedrijf in de klinische fase, heeft vandaag de toplijnresultaten van de MC2-03-C1 Northern Light Fase 2-studie bekendgemaakt, waarbij de veiligheid en werkzaamhe…
MC2 Therapeutics annonce des résultats exceptionnels : profil d’innocuité favorable des gouttes MC2-03 qui permettent une réduction de la souillure cornéenne chez les patients atteints de kératite modérée à sévère…
COPENHAGUE, Danemark–(BUSINESS WIRE)–MC2 Therapeutics annonce des résultats exceptionnels : profil d’innocuité favorable des gouttes MC2-03 qui permettent une réduction de la souillure cornéenne chez les patients atteints de kératite modérée à sévère…
MC2 Therapeutics annuncia risultati topline a dimostrazione del profilo favorevole di sicurezza e della riduzione nello staining corneale di MC2-03 nei pazienti con secchezza oculare con cheratite da moderata a grave
COPENAGHEN, Danimarca–(BUSINESS WIRE)–MC2 Therapeutics A/S, società di stadio clinico specializzata in dermatologia e oculistica, ha oggi annunciato i risultati topline dello studio di fase 2 MC2-03-C1 Northern Lights per la valutazione della sicurez…
OcuSciences Announces Publication Showing OcuMet Beacon Retinal Imager May Detect Glaucoma Earlier Than Current Standard Measures and Be Useful in Assessing Disease Severity
ANN ARBOR, Mich.–(BUSINESS WIRE)–OcuSciences, Inc., a clinical-stage biotechnology company developing retinal imagers to detect early disease by assessing retinal metabolic activity, today announced the online publication of its initial glaucoma stud…
Earnin Survey Shows Majority of Americans Are Delaying Medical Care
PALO ALTO, Calif.–(BUSINESS WIRE)–#earnin–Earnin, an app that allows anyone with a job and a bank account to get paid the minute they leave work, today released the results from a pair of September 2018 surveys. One was conducted online among over 2…
Cell Care Therapeutics Raises $4.3 Million in Seed Funding
MONROVIA, Calif.–(BUSINESS WIRE)–#diabeticretinopathy–Cell Care Therapeutics raises $4.3 million seed funding to develop preclinical-stage drug candidate for the treatment of ocular inflammatory diseases.
Ophthotech Corporation to Report Third Quarter 2018 Financial Results and Host Conference Call on Wednesday, October 31, 2018
NEW YORK–(BUSINESS WIRE)–Ophthotech today announced that it will report its third quarter 2018 financial and operating results on Wednesday, October 31, 2018.
Aerie Pharmaceuticals Establishes GMP PRINT® Production Facility in an Expanded Global Headquarters
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glauco…